Trial
NCT02362230
Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sun Yat-sen University
Collaborators
—
Condition
Metastatic Breast Cancer
Intervention
Icotinib
Why stopped
Difficulty accruing subjects the study accrual was closed
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-01-29